APVO vs. DWTX, AEON, NLSP, CLRB, CHRO, KPRX, TSBX, BMRA, TCRT, and TRAW
Should you be buying Aptevo Therapeutics stock or one of its competitors? The main competitors of Aptevo Therapeutics include Dogwood Therapeutics (DWTX), AEON Biopharma (AEON), NLS Pharmaceutics (NLSP), Cellectar Biosciences (CLRB), Chromocell Therapeutics (CHRO), Kiora Pharmaceuticals (KPRX), Turnstone Biologics (TSBX), Biomerica (BMRA), Alaunos Therapeutics (TCRT), and Traws Pharma (TRAW). These companies are all part of the "pharmaceutical products" industry.
Aptevo Therapeutics vs. Its Competitors
Dogwood Therapeutics (NASDAQ:DWTX) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.
9.1% of Dogwood Therapeutics shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 3.9% of Dogwood Therapeutics shares are owned by insiders. Comparatively, 0.1% of Aptevo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Dogwood Therapeutics' return on equity of 0.00% beat Aptevo Therapeutics' return on equity.
Dogwood Therapeutics has higher earnings, but lower revenue than Aptevo Therapeutics.
In the previous week, Dogwood Therapeutics had 1 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 2 mentions for Dogwood Therapeutics and 1 mentions for Aptevo Therapeutics. Aptevo Therapeutics' average media sentiment score of 1.89 beat Dogwood Therapeutics' score of 0.94 indicating that Aptevo Therapeutics is being referred to more favorably in the news media.
Dogwood Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500. Comparatively, Aptevo Therapeutics has a beta of 5.58, suggesting that its stock price is 458% more volatile than the S&P 500.
Dogwood Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 112.77%. Aptevo Therapeutics has a consensus price target of $219,040.00, indicating a potential upside of 7,501,269.86%. Given Aptevo Therapeutics' higher probable upside, analysts plainly believe Aptevo Therapeutics is more favorable than Dogwood Therapeutics.
Summary
Dogwood Therapeutics beats Aptevo Therapeutics on 6 of the 10 factors compared between the two stocks.
Get Aptevo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding APVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptevo Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:APVO) was last updated on 7/16/2025 by MarketBeat.com Staff
Free APVO Stock Alerts